ABSTRACT

Background: This study aims to evaluate the surgical treatment outcomes of giant mediastinal tumors.

Methods: Between July 2013 and July 2018, medical data of a total of 31 patients (26 males, 5 females; mean age 27.7±8.2 years; range, 18 to 56 years) who underwent radical surgery for a giant mediastinal tumor in our center and 47 cases (26 males, 21 females; mean age 45.4±16.7 years; range, 19 to 62 years) of giant mediastinal tumors retrieved from the National Center for Biotechnology Information database were retrospectively reviewed. Two-year overall survival and disease-free survival rates of the patients were evaluated.

Results: All patients underwent radical surgery (R0 resection). Symptoms caused by giant mediastinal tumors were relieved after radical surgery during follow-up. The two-year overall survival and disease-free survival rates were 100% and 86.7%, respectively, indicating a good prognosis. The surgical procedures for malignancies were more difficult than those for benign pathologies.

Conclusion: Radical surgery is the mainstay for treatment of giant mediastinal tumors to relieve symptoms in a short period of time and to achieve a good prognosis for up to two years, regardless of adjuvant therapy. The surgical route should be cautiously planned before radical surgery to reduce complications.

Keywords: Giant mediastinal tumor, prognosis, radical surgery.

A giant mediastinal tumor (GMT), defined as occupying half of the hemithorax or having a diameter >10 cm, is an extremely rare entity characterized by a diversity of symptoms, including chest pain, cough, dyspnea, and dysphagia, as well as potentially lethal respiratory failure and malignant arrhythmias.[1-4] Radical surgery (RS) is recommended for the treatment of a GMT. However, a higher risk of perioperative complications is associated with such large tumors.[5,6]
Angelopoulos et al.\[3\] reported an old female with a huge mediastinal malignant schwannoma who suffered from systemic sepsis and multiple organ dysfunction after surgery. A similar case was also reported by Furūk et al.\[5\] in a young female with a large ganglioneuroma suffering from an acute paraplegia with a spinal cord lesion due to vertebral artery injury.

Up to date, there is no similar study including meta-analysis, randomized-controlled trials, and systemic retrospective or observational studies. In this study, we aimed to evaluate the surgical treatment outcomes of GMTs and to develop an evidence-based strategy for the treatment of GMTs.

**PATIENTS AND METHODS**

This single-center, retrospective study was conducted at the First Affiliated Hospital of Chongqing Medical University, Department of Thoracic and Cardiovascular Surgery between July 2013 and July 2018. Medical data of a total of 31 patients (26 males, 5 females; mean age 27.7±8.2 years; range, 18 to 56 years) who underwent radical surgery for a GMT in our center and 47 cases (26 males, 21 females; mean age 45.4±16.7 years; range, 19 to 62 years) of GMTs retrieved from the National Center for Biotechnology Information (NCBI) database were retrospectively reviewed. Inclusion criteria were as follows: age >16 years; having mediastinal tumors involving half of the hemithorax or having a diameter of >10 cm; and previous GMT surgery regardless of radical or palliative. Exclusion criteria were as follows: patients who were unable to tolerate surgery or were unwilling to undergo surgery; and those undergoing exploratory GMT surgery. A written informed consent was obtained from each patient. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (No. 00734800). The study was conducted in accordance with the principles of the Declaration of Helsinki.

Forty-seven cases of GMTs reported between January 2008 and December 2018 were retrieved from the NCBI database (https://www.ncbi.nlm.nih.gov/). Among these tumors, 23 were malignant and 24 benign. The malignant tumors consisted of nine liposarcomas,\[4,13\] five thymomas (Masaoka Stage I-II),\[14-18\] three schwannomas,\[19,20\] one gangliocytoma,\[21\] one angiolipoma,\[22\] one endodermal sinus tumor,\[23\] one epithelioid angiosarcoma,\[24\] one stromal tumor,\[25\] and one solitary fibrous tumor.\[26\] The benign tumors included five mature teratomas,\[27-31\] five schwannomas,\[2,22-35\] five thymolipomas,\[36-40\] two leiomyomas,\[41,42\] two thymomas (Masaoka Stage I),\[43,44\] one pericardial cyst,\[45\] one germ cell tumor,\[46\] one cavernous hemangioma,\[47\] one lymphangioma,\[48\] and one pericardial paraganglioma.\[49\]

Tumor pathology was determined by two pathologists at the Department of Pathology of Chongqing Medical University. Seventeen tumors were reported as malignant (6 thymomas [Masaoka Stage I-III], two liposarcomas, two teratomas, two thymic squamous cell carcinomas, 2 fibrous histiocytomas, 2 spermatocytomas, and 1 non-Hodgkin lymphoma), while 14 were reported as benign (5 mature teratomas, 2 substernal goiters, 2 schwannomas, 2 solitary fibrous tumors, 1 case of Castleman disease, 1 case of fibromatosis, and 1 thymolipoma).

In terms of the tumor location, two tumors originated from the neck and extended toward the anterosuperior mediastinum. One tumor originated from the superior and anterior mediastinum and extended toward the neck. Five tumors originated from the superior mediastinum and extended toward one hemithorax. Twenty-three tumors were located primarily in one hemithorax.

All patients underwent RS. The surgical route was determined based on the tumor location and the invaded structures. Radical surgery (R0 resection) of a malignant tumor was defined as removal of all invaded structures along with the tumor itself, while RS of a benign tumor was defined as removal of the tumor only. Adjuvant therapy (AT) protocols after RS were decided by a multidisciplinary team consisting of physicians, oncologists, and surgeons.

Prognosis was evaluated based on two-year overall survival (OS) and two-year disease-free survival (DFS) rates. Two-year OS was defined as the percentage of patients who survived for at least two years after RS, while two-year DFS was defined as the percentage of patients who survived for at least two years after RS with no relapse or metastasis.

**Statistical analysis**

Statistical analysis was performed using the IBM SPSS for Windows version 19.0 software (IBM Corp., Armonk, NY, USA). Descriptive data were expressed in mean ± standard deviation (SD), median (min-max) or number and frequency. The Student’s t-test was used to analyze significant differences between the groups. The chi-square test was used to analyze differences between the malignant and benign tumor groups. Survival analysis was carried out using the
Kaplan-Meier plot. A $p$ value of $<0.05$ was considered statistically significant.

**RESULTS**

The symptoms associated with GMTs are listed in Table 1. Although the majority of patients with GMTs treated in our center had no obvious symptoms, nearly half the cases retrieved from the NCBI database had typical clinical symptoms. The discrepancy between these two cohorts was attributed to the different pathological spectrums and tumor size and location. Certain fatal symptoms (e.g., superior vena cava [SVC] syndrome, respiratory failure, and hemoptysis) primarily occurred in patients with malignancies. Hematological disorders (i.e., Cooley anemia in our cohort) occurred in patients with mature teratomas. After RS, the symptoms of dyspnea, dysphagia, cough, chest pain, hemoptysis, and palpitation in both cohorts were relieved or eliminated during a relatively short follow-up period. In addition, SVC syndrome was relieved within two weeks after RS, while hoarseness was eliminated over a period of one month and Cooley anemia had resolved within six months.

The invaded structures, surgical modes, and routes are listed in Table 2. None of the benign tumors involved the surrounding tissues. However, the malignant tumors invaded different tissues in both our cohort and the cases retrieved from the NCBI database. The invaded tissues included vessels (i.e., SVC, innominate vein, subclavian artery, aorta, and pulmonary artery), diaphragm, lung, pericardium, esophagus, nerves, and thoracic wall. The surgical route was determined based on the tumor location and the invaded tissues. A lateral incision was the most common route, as most tumors were primarily located in one hemithorax. A collar incision was added, if the neck was involved. A clamshell or bilateral incision was a more optimal choice, if the tumor extended toward both hemithorax. In our cohort, piecemeal resection was more commonly used for malignancies ($p=0.005$). However, among the cases retrieved from the NCBI database, there was no significant difference in the use of en bloc resection between malignant and benign tumors ($p=0.087$), as nearly all surgical procedures included en bloc resection.

Demographic characteristics of both cohorts and associated complications are summarized in Table 3. In our cohort, patients with malignancies were likely to be younger than those with benign tumors ($p=0.019$), while there was no significant difference in the age among the cases retrieved from the NCBI

### Table 1. Clinical symptoms of GMTs in our cohort and cases retrieved from NCBI database

| Symptoms                | Our cohort |          |          | NCBI database |          |          |
|-------------------------|------------|----------|----------|---------------|----------|----------|
|                         | Total (n=31) | Benign (n=14) | Malignancy (n=17) | Total (n=47) | Benign (n=24) | Malignancy (n=23) |
| Dyspnea                 | 4          | 1        | 3        | 24           | 12       | 12       |
| Cough                   | -          | -        | -        | 12           | 7        | 5        |
| Dysphagia               | 1          | 1        | -        | 5            | 3        | 2        |
| Chest pain              | -          | -        | -        | 16           | 5        | 11       |
| Fever                   | -          | -        | -        | 2            | 1        | 1        |
| Hemoptysis              | -          | -        | -        | 3            | 1        | 2        |
| Hoarseness              | 1          | 1        | -        | -            | -        | -        |
| Nausea and vomiting     | -          | -        | -        | 1            | 1        | -        |
| Weight loss             | -          | -        | -        | 2            | 1        | 1        |
| Digital clubbing        | -          | -        | -        | 1            | -        | 1        |
| Palpitation             | -          | -        | -        | 4            | -        | 4        |
| Respiratory failure     | -          | -        | -        | 2            | 1        | 1        |
| SVC syndrome            | 4          | -        | 4        | -            | -        | -        |
| Cooley anemia           | 1          | 1        | -        | -            | -        | -        |

GMTs: Giant mediastinal tumors; NCBI: National Center for Biotechnology Information.; SVC: Superior vena cava.
database (p=0.22). The mean maximum diameter of malignant tumors was higher than that of benign tumors in our cohort (p=0.039), while there was no significant difference among the cases retrieved from the NCBI database (p=0.44). Compared to benign tumors, malignancies had a longer mean duration of RS (218.8±57.8 min vs. 162±21.8 min, respectively; p=0.002), chest drainage (5.9±1.6 days vs. 4.5±0.6 days, respectively; p=0.004), hospital stay (7.9±1.6 days vs. 6.5±0.6 days, respectively; p=0.004), and a higher amount of intraoperative blood loss (1,550±828 mL vs. 1,023±147 mL, respectively; p=0.023). There was no mortality during the perioperative period. Arrhythmias after RS were relieved and eliminated during the follow-up period without medical intervention. Chylothorax occurring

| Invaded structure                  | Our cohort | NCBI database |
|-----------------------------------|------------|---------------|
| Diaphragm                         | 3          | 1             |
| Pulmonary parenchyma              | 7          | 2             |
| Pericardium                       | 4          | 1             |
| SVC                               | 4          | -             |
| Esophagus                         | 1          | 2             |
| LIV                               | 3          | 2             |
| Subclavian artery                 | -          | 1             |
| Phrenic nerve                     | -          | 2             |
| Thoracic wall                     | 1          | 1             |
| Pulmonary artery trunk            | 1          | -             |
| Aorta                             | -          | 1             |
| Tumor capsule                     | -          | 1             |

| Surgical mode                     | Our cohort | NCBI database |
|-----------------------------------|------------|---------------|
| Partial diaphragm resection       | 3          | 1             |
| Lobectomy                         | 2          | 1             |
| Pulmonary wedge resection         | 5          | 1             |
| Pneumonectomy                     | 1          | -             |
| Partial pericardium resection     | 5          | 1             |
| SVC angioplasty                   | 3          | -             |
| SVC replacement                   | 1          | -             |
| Esophagectomy                     | 1          | 2             |
| LIV angioplasty                   | 3          | 2             |
| Thoracic wall resection and重建   | 1          | 1             |

| Surgical route                    | Our cohort | NCBI database |
|-----------------------------------|------------|---------------|
| Lateral                           | 23         | 29            |
| Median sternotomy                 | -          | 12            |
| Neck collar                       | -          | 1             |
| Neck collar + median sternotomy   | 3          | 12            |
| Hemi-Clamshell                    | 5          | 3             |
| Clamshell                         | -          | 1             |
| Bilateral                         | -          | 1             |

| Radical or palliative             | Our cohort | NCBI database |
|-----------------------------------|------------|---------------|
| Radical                           | 31         | 45            |
| Palliative                        | -          | 24            |

| Surgical strategy                 | Our cohort | NCBI database |
|-----------------------------------|------------|---------------|
| En bloc                           | 15         | 46            |
| Piecemeal                         | 16         | 2             |

NCBI: National Center for Biotechnology Information; SVC: Superior vena cava; LIV: Left innominate vein.
Table 3. Demographic and clinical data of GMTs in our cohort and cases retrieved from NCBI database

|                      | Our cohort | NCBI database |
|----------------------|------------|---------------|
|                      | Total      | Benign (n=14) | Malignancy (n=17) | Total      | Benign (n=24) | Malignancy (n=23) | p*     |
|                      | (n=31)     |               |                  | (n=47)     |               |                  |        |
| n                    | Mean±SD    | n Mean±SD     | n Mean±SD       | n Mean±SD  | n Mean±SD     | n Mean±SD        |        |
| Age (year)           | 27.8±8.2   | 31.1±8.6      | 24.2±6.4        | 0.019      | 45.4±16.7     | 42.3±15.4        | 0.22   |
| Sex                  |            |               |                  |            |               |                  |        |
| Male                 | 12         | 14            |                  | 26         | 13            | 13               | 0.37   |
| Female               | 26         | 5             |                  |            |               |                  |        |
| Maximum diameter (cm)| 18.1±5.1   | 16.4±4.7      | 19.5±5.0        | 0.039      | 20.8±8.1      | 19.8±7.5         | 0.44   |
| Adjuvant therapy     |            |               |                  |            |               |                  |        |
| Chemotherapy         | 10         | 10            | -                | 5          | -             | 5                |        |
| Radiotherapy         | -          | -             | -                | 4          | -             | 4                |        |
| Chemoradiotherapy    | -          | -             | -                | 1          | -             | 1                |        |
| Prognosis            |            |               |                  |            |               |                  |        |
| Relapse              | 3          | -             | 3                | 1          | -             | 1                |        |
| Metastasis           | 1          | -             | 1                | -          | -             | -                |        |
| DFS (year)           | -          | -             | 2.3±0.9          | -          | -             | -                | 1.9±1.7|
| OS (year)            | -          | -             | 2.6±0.9          | -          | -             | -                | 1.8±1.4|
| Complication         |            |               |                  |            |               |                  |        |
| Arrhythmias          | 2          | 1             | 1                | -          | -             | -                |        |
| Cholera              | 1          | -             | 1                | -          | -             | -                |        |
| Vocal cord paralysis | -          | -             | -                | 1          | 1             | -                |        |
| Hemithorax           | -          | -             | -                | 1          | -             | 1                |        |
| Flaccid paralysis    | -          | -             | -                | 1          | -             | 1                |        |

GMTs: Giant mediastinal tumors; NCBI: National Center for Biotechnology Information; SD: Standard deviation; DFS: Disease-free survival; OS: Overall survival; * Benign vs. malignant tumors; * p<0.05.
after RS was eliminated by fasting and administration of somatostatin for three days. The use of AT after RS is also shown in Table 3. Seven patients refused to receive AT after RS. No neo-AT or radiotherapy was used.

The patients diagnosed with benign tumors survived with no relapse or metastasis since the last follow-up (Table 3). All 17 patients with malignant tumors survived since the last follow-up, of whom 13 remained disease-free. However, one of 17 patients diagnosed with a thymoma (Masaoka Stage III) developed pulmonary metastasis two years after RS, while two others diagnosed with thymic squamous carcinomas and one with a liposarcoma had a relapse at 1.5, 1.2, and two years after RS, respectively. The patients with pulmonary metastasis or relapse refused a second RS and, thus, only received palliative care. The two-year OS rate for malignancies was 100% (17/17), while the two-year DFS was 86.7% (15/17) (Figure 1). Of the cases retrieved from the NCBI database, only one diagnosed with a liposarcoma had a relapse at 1.25 years after RS and underwent a second RS and survived disease-free for another three years. In our cohort, two of 10 patients who received AT had a relapse after RS, while two others who received no AT developed pulmonary metastasis and relapse, respectively. There were no significant differences in the incidences of relapse and metastasis between the patients who receive and did not receive AT (p=0.682). Of the 13 cases retrieved from the NCBI database who received no AT, only one had a relapse, while none developed metastasis. In our cohort, there was no significant difference in the mean DFS duration between the two patients who relapsed after AT and the two patients who relapsed or developed metastasis without AT (1.8±0.4 years vs. 2.1±1.3 years, respectively; p=0.83).

In our cohort, four patients diagnosed with malignancies developed SVC syndrome. The pathology of these patients included one case of thymic squamous cell carcinoma, one thymoma (Masaoka Stage III), and one malignant teratoma. The mean DFS and OS times were 2.3±0.5 and 2.8±1.0 years, respectively. All four of these patients received chemotherapy after RS and survived since the last follow-up. Recurrence occurred in one patient diagnosed with thymic squamous cell carcinoma at two years after RS, while the other three patients remained disease-free.

**DISCUSSION**

In the literature, most studies of GMTs are published as case reports. Our study is, therefore, valuable as it analyzed a series of clinical cases for guiding the treatment of GMTs. Our study results showed a good prognosis in both our cohort and the cases retrieved from the NCBI database using RS. Only four (23.5%) of 17 patients in our cohort with malignancies developed metastasis or relapse, but survived since the last follow-up after RS. The two-year OS and two-year DFS rates of all patients with malignancies were 100% and 86.7%, respectively. Of the cases retrieved from the NCBI database, only one who did not receive AT after RS had a relapse. Therefore, prognosis was better after RS. Nonetheless, it still remains controversial whether AT is required for malignancies after RS.

Radical surgery can relieve or eliminate symptoms during follow-up and improve quality of life of patients. In our cohort and the cases retrieved from the NCBI database, benign tumors primarily caused squeezing symptoms of dyspnea, cough, dysphagia, nausea, and vomiting. Meanwhile, malignancies are associated with invasive and systemic symptoms in addition to squeezing symptoms, such as chest pain, hemoptysis, and palpitation. Under emergent circumstances, such as acute respiratory failure and SVC syndrome, RS can be a life-saving option. In our cohort and the cases retrieved from the NCBI database, the symptoms of squeezing and invasion were relieved during a short-term follow-up after RS. Acute SVC syndrome may also result in sudden death. In our cohort, SVC syndrome of four patients

![Figure 1. Kaplan-Meier survival analysis.](image)

OS: Overall survival; DFS: Disease-free survival; Cum: Cumulative.
was relieved within two weeks after RS. The GMTs, regardless of benign or malignant, may accompany endocrinological or hematological disorders such as hyperparathyroidism and chronic dyserythropoietic anemia. Cooley anemia in our cohort was gradually rectified by RS during follow-up.

Currently, RS remains the first-choice option for treatment of GMTs. However, the surgical route and strategy are critical for surgical safety and successful R0 resection. A lateral thoracotomy is recommended for tumors primarily located in one hemithorax, while median sternotomy is recommended for tumors at the anterosuperior mediastinum. The hemi-clamshell procedure should be considered, if the tumor is located at the anterior mediastinum and extends into one hemithorax, while the clamshell or bilateral thoracotomy is recommended, if the tumor extends into the bilateral hemithorax. A collar incision should be considered, if a collar incision plus median sternotomy is recommended, if the tumor is located at the anterosuperior mediastinum and involves the neck. Mini-invasive techniques are not recommended for resection of GMTs, except for cystic lesions or solid lesions located at the postero inferior mediastinum, which has a larger space.

Mediastinal tumors may adhere to or invade the surrounding tissues including the vessels, lung, thoracic wall, diaphragm, and pericardium. To achieve R0 resection, the tumor and the invaded surrounding tissues should be completely removed. Injury to the vital tissues (e.g., great vessels and recurrent laryngeal nerve) should be avoided during RS. Therefore, the surgical route and mode should be cautiously planned. Furthermore, extracorporeal membrane oxygenation or cardiopulmonary bypass is recommended, if angioplasty or prosthesis replacement is required. Piecemeal resection is an alternative option, if the tumor cannot be removed en bloc, due to the high risk of massive hemorrhage or injury to vital tissues.

The main limitations of the present study include its retrospective and single-center design with a small sample size. Therefore, further large-scale, multi-center, prospective studies are needed to confirm these findings.

In conclusion, radical surgery is the paramount strategy for the treatment of giant mediastinal tumors to relieve symptoms within a short period of time and achieve a good prognosis in the long-term. The surgical route and mode should be cautiously planned before RS to reduce the rate of intraoperative complications.

We believe that the outcomes of this study provide evidence to guide the treatment of giant mediastinal tumors in clinical practice.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
This study was supported by the National Natural Science Foundation of China (81400590).

REFERENCES
1. Schweigert M, Kaiser J, Fuchs T, Stein HJ. Thymoma within a giant congenital thymic cyst. Interact Cardiovasc Thorac Surg 2011;13:442-3.
2. Das A, Choudhury S, Basuthakur S, Mukhopadhyay A, Mukherjee S. Massive hemoptysis: a rare presentation of posterior mediastinal giant, benign vagal schwannoma. Arch Iran Med 2014;17:779-82.
3. Angelopoulos E, Elefteriou K, Kryiakopoulos G, Athanassiadi K, Rontogianni D, Routsi C. A Giant Intrathoracic Malignant Schwannoma Causing Respiratory Failure in a Patient without von Recklinghausen's Disease. Case Rep Med 2016;2016:2541290.
4. Arrarás-Martínez MJ, Rieger-Reyes C, Panadero-Paz C, Landa-Oviedo HS, García-Tirado J. Giant primary mediastinal liposarcoma: A rare cause of atrial flutter. Asian Cardiovasc Thorac Ann 2015;23:1121-4.
5. Furák J, Géczi T, Tiszlavicz L, Lázár G. Postoperative paraplegia after resection of a giant posterior mediastinal tumour. Importance of the blood supply in the upper spinal cord. Interact Cardiovasc Thorac Surg 2011;12:855-6.
6. Okuno M, Kawashima M, Miura K, Kadota E, Goto S, Kato M. Resection of giant mediastinal liposarcoma using the hemi-clamshell incision. Gen Thorac Cardiovasc Surg 2010;58:654-6.
7. Vanoverbeke H. Resection of giant mediastinal liposarcoma. Acta Cardiol 2014;69:311-2.
8. Taki K, Watanabe M, Iwagami S, Nagai Y, Iwatsuki M, Ishimoto T, et al. Giant liposarcoma of the posterior mediastinum and retroperitoneum. BMJ Case Rep 2011;2011:bcr0620114341.
9. Gethin-Jones TL, Evans NR 3rd, Morse CR. Surgical management of mediastinal liposarcoma extending from hypopharynx to carina: case report. World J Surg Oncol 2010;8:13.
10. Billé A, Garofalo G, Leo F, Pastorino U. Giant liposarcoma elongating mediastinal vessels with intrathoracic inferior vena cava replacement. Eur J Cardiothorac Surg 2013;44:570-2.
11. Ma J, Zhang HM, Zhang LW, Zheng MW, Yu M. Primary mediastinal giant liposarcoma with smooth muscle and neural differentiation: A case report. Oncol Lett 2015;9:2667-9.
12. Huang W, Jiang GN. Resection of giant mediastinal liposarcoma via ‘dash shape’ incision. J Surg Case Rep 2017;2017:rijw219.
Surgery for giant mediastinal tumors

Fang and Qin.

13. Lin F, Pu Q, Ma L, Liu C, Mei J, Liao H, et al. Successful resection of a huge mediastinal liposarcoma extended to the bilateral thorax. Thorac Cancer 2016;7:373-6.

14. Filosso PL, Delsedime L, Cristofori RC, Sandri A. Ectopic pleural thymoma mimicking a giant solitary fibrous tumour of the pleura. Interact Cardiovasc Thorac Surg 2012;15:930-2.

15. Zhao W, Fang W. Giant thymoma successfully resected via hemiclamesh thoracotomy: a case report. J Thorac Dis 2016;8:E677-80.

16. Kitada M, Sato K, Matsuda Y, Hayashi S, Tokusashi Y, Miyokawa N, et al. Ectopic thymoma presenting as a giant intrathoracic tumor: a case report. World J Surg Oncol 2011;9:66.

17. Spartalis ED, Karatzas T, Konofaos P, Karagiouzis G, Kouraklis G, Tomos P. Unique presentation of a giant mediastinal tumor as kyphosis: a case report. J Med Case Rep 2012;6:99.

18. Fazlıoğulları O, Atalan N, Gürer O, Akgün S, Arsan S. Cardiac tamponade from a giant thymoma: case report. J Cardiothorac Surg 2012;7:14.

19. Su JW, Chua YL, Ong BH, Lim CH. Resection of a giant malignant mediastinal peripheral nerve sheath tumour under cardiopulmonary bypass. Singapore Med J 2009;50:e199-200.

20. Wang J, Yan J, Ren S, Guo Y, Gao Y, Zhou L. Giant neurogenic tumors of mediastinum: report of two cases and literature review. Chin J Cancer Res 2013;25:259-62.

21. Hayat J, Ahmed R, Alizai S, Awan MU. Giant ganglioneuroma of the posterior mediastinum. Interact Cardiovasc Thorac Surg 2011;13:344-5.

22. Liu P, Che WC, Ji HJ, Jiang ZM. A giant infiltrating angiolipoma of the mediastinum: a case report. J Cardiothorac Surg 2016;11:164.

23. Chaudhry IU, Rahhal M, Khurshid I, Mutairi H. Radical surgical resection for giant primary mediastinal endodermal sinus tumour with pulmonary metastasis after chemotherapy: can be curative. BMJ Case Rep 2014;2014:bcr201404662.

24. Tane S, Tanaka Y, Tauchi S, Uchino K, Nakai R, Yoshimura M. Radically resected epithelioid angiosarcoma that originated in the mediastinum. Gen Thorac Cardiovasc Surg 2011;59:503-6.

25. Tanimura S, Saito Y, Honma K, Koizumi K. Surgical case of giant malignant mesenchymoma in the posterior mediastinum that recurred in the bilateral mediastinum. J Nippon Med Sch 2008;75:212-5.

26. De Raet J, Sacré R, Hoorens A, Fletcher C, Lamote J. Malignant giant solitary fibrous tumor of the mediastinum. J Thorac Oncol 2008;3:1068-70.

27. Pattynaik MK, Majhi PC, Nayak AK, Senapati D. A rare presentation of a huge mature mediastinal teratoma with right lung cavitation. BMJ Case Rep 2014;2014:bcr201403835.

28. Zhao H, Zhu D, Zhou Q. Complete resection of a giant mediastinal teratoma occupying the entire right hemithorax in a 14-year-old boy. BMC Surg 2014;14:56.

29. Omachi N, Kawaguchi T, Shimizu S, Okuma T, Kitaichi M, Atagi S, Yoon HE, Matsumura A, et al. Life-threatening and Rapidly Growing Teratoma in the Anterior Mediastinum. Intern Med 2015;54:2487-9.

30. Rothermel L, Gilkeson R, Markowitz AH, Schröder C. Thoracoscopic resection of a giant teratoma compressing the right heart. Interact Cardiovasc Thorac Surg 2013;17:594-7.

31. Rothermel L, Gilkeson R, Markowitz AH, Schröder C. Thoracoscopic resection of a giant teratoma compressing the right heart. Interact Cardiovasc Thorac Surg 2013;17:594-7.

32. Kato M, Shiota S, Shiga K, Takagi H, Mori H, Sekiya M, et al. Benign giant mediastinal schwannoma presenting as cardiac tamponade in a woman: a case report. J Med Case Rep 2011;5:61.

33. Gueldich M, Bentati A, Chakroun A, Abid H, Kammoun S, M'saad S, et al. Giant cystic schwannoma of the middle mediastinum with cervical extension. Libyan J Med 2015;10:27409.

34. Wu Y, Zhang J, Chai Y. Giant mediastinal schwannoma located in the lower right side of the chest. Niger J Clin Pract 2016;19:678-80.

35. Jang JY, Kim JS, Choe JW, Kim MK, Jung JW, Choi JC, et al. A case of giant, benign schwannoma associated with total lung collapse by bloody effusion. Tuberc Respir Dis (Seoul) 2013;75:71-4.

36. Mourad OM, Andrade FM, Abrahão P, Monnerat A, Judice LF. Asymptomatic giant mediastinal mass: a rare case of thymolipoma. J Bras Pneumol 2009;35:1049-52.

37. Obeso Carillo GA, García Fontán EM, Cañizares Carretero MA. Giant thymolipoma: case report of an unusual mediastinal tumor. Arch Bronconeumol 2014;50:557-9.

38. Ganesh Y, Yadala V, Nanlin Y, Dal A, Raju AD. Huge mediastinal mass with minimal symptoms: thymolipoma. BMJ Case Rep 2011;2011:bcr0520102984.

39. Mohan Rao PS, Moorthy N, Shankarappa RK, Bhat P, Nanjappa MC. Giant mediastinal thymolipoma simulating cardiomegaly. J Cardiol 2009;54:326-9.

40. Pei G, Han Y, Zhou S, Liu Z. Giant mediastinal thymolipoma in a patient with Gardner's syndrome. Thorac Cancer 2015;6:808-11.

41. Uno A, Sakurai M, Onuma K, Yamane Y, Kurita K, Hayashi I, et al. A case of giant mediastinal leiomyoma with long-term survival. Tohoku J Exp Med 1988;156:1-6.

42. Haratake N, Shoji F, Kozuma Y, Okamoto T, Maehara Y. Giant Leiomyoma Arising from the Mediastinal Pleura: A Case Report. Ann Thorac Cardiovasc Surg 2017;23:153-6.

43. Limmer S, Merz H, Kujath P. Giant thymoma in the anterior-inferior mediastinum. Interact Cardiovasc Thorac Surg 2010;10:451-3.

44. Saito T, Makino T, Hata Y, Koezuka S, Otsuka H, Koezuka S, et al. Giant thymoma successfully resected via anterolateral thoracotomy: a case report. J Cardiothorac Surg 2015;10:110.

45. Abkayarak H, Yildirim S, Simsek M, Oc M. A rare giant pericardial cyst mimicking a paracardiac mass. Cardiovasc J Afr 2016;27:e7-e9.

46. Traibi A, Bakkali YE, Hammoumi ME, Kabiri el H. Giant mediastinal germ cell tumor. Intern Med 2011;50:1261-2.
47. Kaya SO, Samancilar O, Usluer O, Acar T, Yener AG. Giant Cavernous Haemangioma of the Anterior Mediastinum. Eurasian J Med 2015;47:216-7.

48. Sokouti M, Rostambeigi N, Halimi M, Rasihashemi SZ. A huge lymphangioma mimicking pleural effusion with extension to both chest cavities: a case report and review of literature. Iran J Med Sci 2015;40:181-4.

49. Yamamoto Y, Kodama K, Yamato H, Takeda M. Successful Removal of Giant Intrapericardial Paraganglioma via Posterolateral Thoracotomy. Case Rep Surg 2014;2014:308462.

50. Ishikawa M, Sumitomo SI, Imamura N, Nishida T, Mineura K. A rare case of mediastinal functioning parathyroid adenoma removed successfully with thoracoscopy. J Surg Case Rep 2017;2017:rjx070.

51. Oliveira CC, Felisberto G Junior, Camolese VH, Hasimoto EN, Cataneo DC, Cataneo AJ, et al. Myelolipoma of the posterior mediastinum in a patient with chronic dyserythropoietic anemia. Autops Case Rep 2016;6:35-9.

52. Bai SZ, Feng ZH, Gao R, Dong Y, Bi YP, Wu GF, et al. Development and application of a rapid rehabilitation system for reconstruction of maxillofacial soft-tissue defects related to war and traumatic injuries. Mil Med Res 2014;1:11.